论文部分内容阅读
目的：从基因水平探讨精神分裂症患者对利培酮的临床治疗效应存在个体差异的原因。方法：对79名精神分裂症患者进行为期6周的利培酮治疗，评价临床疗效，同时就5-HT2A受体基因启动子区域-1438G/A多态位点进行基因型和等位基因频率检测，据此分析基因型和等位基因频率与临床治疗效应的关系。 结果：受体-1438G/A的基因型和等位基因频率与利培酮的临床总体疗效有关(?2=13.60；P<0.01)， GG基因型或等位基因为G的患者临床疗效相对较差。结论：精神分裂症患者5-HT2A受体-1438G/A的基因型和等位基因可以作为利培酮临床疗效的预测因子。5-HT2A受体可能为非典型抗精神病药物作用的靶受体。
OBJECTIVE: To explore the causes of individual differences in the clinical therapeutic effects of risperidone in patients with schizophrenia at the genetic level. Methods: 79 patients with schizophrenia were treated with risperidone for 6 weeks to evaluate the clinical efficacy. At the same time, the genotype and allele frequency of -1438G / A polymorphism in 5-HT2A receptor gene promoter region Test, according to the analysis of genotype and allele frequency and clinical treatment effect. Results: The genotype and allele frequencies of receptor-1438G / A were related to the overall clinical efficacy of risperidone (2 2 = 13.60; P <0.01). The clinical efficacy of patients with GG genotype or allele G was Poor. Conclusion: The genotypes and alleles of 5-HT2A receptor-1438G / A in schizophrenia may serve as predictors of the clinical efficacy of risperidone. The 5-HT2A receptor may be the target receptor for atypical antipsychotics.